Market Access News | pharmaphorum

News

Lilly aims for new indication for Taltz

Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.

News

Greece to probe claims that Novartis bribed former leaders

Scandal could be biggest in country's history, says politician

News

Vertex's latest cystic fibrosis combination approved in US

Vertex’s quest to treat a wider group of patients with cystic fibrosis (CF) continues after the FDA approved its latest combination therapy, Symdeko.

News

NICE rejects Biomarin's £520K per year rare disease drug

Company will negotiate access scheme

News

Boehringer latest to axe Alzheimer's drug

Company will trial BI 409306 in schizophrenia instead.

News

Ramaswamy's Roivant signs diabetes drug deal with Poxel

Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment

Lilly aims for new indication for Taltz

Greece to probe claims that Novartis bribed former leaders

Vertex's latest cystic fibrosis combination approved in US

NICE rejects Biomarin's £520K per year rare disease drug

Boehringer latest to axe Alzheimer's drug

Ramaswamy's Roivant signs diabetes drug deal with Poxel

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks